How we grade evidence
- L1 Multiple randomized controlled trials with consistent effect; systematic reviews support the intervention.
- L2 At least one RCT plus larger case series; effect direction consistent but magnitude debated.
- L3 Case series, small pilots, animal data extrapolated; plausible but unproven at scale.
- L4 Testimonial, marketing, or fringe-diagnosis claims without peer-reviewed evidence of benefit.
Why the subtype question changes everything
"Peripheral neuropathy" is not one condition. Diabetic peripheral neuropathy has clear pathophysiology (chronic hyperglycemia driving axonal damage, microvascular ischemia, and impaired regeneration) and a growing regenerative-medicine literature. Idiopathic small-fiber neuropathy — by definition without an identified cause — has less mechanistic clarity and a much smaller published evidence base. Clinics that market "stem cells for neuropathy" without distinguishing the subtype are papering over that gap.
What the diabetic neuropathy evidence shows
The most studied regenerative approach in diabetic neuropathy is intramuscular injection of bone-marrow-derived or adipose-derived mesenchymal stromal cells into the calves and feet. Small controlled trials — mostly from centers in Asia and Europe — have shown improvements in nerve conduction velocity, sural nerve function, pain scores, and vibration sensation over 3–12 months. Effect sizes are modest, dropout is real, and larger phase-3 trials remain uncommon.
The mechanistic story is coherent: MSCs release neurotrophic factors (NGF, BDNF, VEGF) and modulate the local vascular environment. In a disease driven partly by microvascular insufficiency, that has a plausible target. The evidence supports "reasonable investigational option in refractory diabetic neuropathy" — not "cure."
What the idiopathic neuropathy evidence shows
Much less. There are case reports and small case series applying similar protocols to idiopathic small-fiber neuropathy and to chemotherapy-induced peripheral neuropathy, with mixed results. Without an underlying cause identified, it is harder to know what the therapy is trying to correct, and outcome measures like intraepidermal nerve fiber density are not consistently improved across studies.
Why this matters practically
- Diabetic neuropathy patients should still optimize glycemic control before or during any regenerative treatment — cells cannot outrun ongoing hyperglycemia damage.
- Idiopathic neuropathy patients should have a full workup (B12, thyroid, autoimmune, monoclonal gammopathy, celiac, alcohol history, medication review) before assuming their condition is truly idiopathic.
- Chemotherapy-induced neuropathy is its own subtype with early trial data but no established protocols.
Realistic outcome expectations
Best published results in diabetic neuropathy show meaningful pain reduction in roughly half to two-thirds of treated patients, with more modest changes in objective nerve function measures. Restoration to fully normal sensation is uncommon. Anyone promising "reversal" of established neuropathy is overstating what regenerative medicine can currently deliver.
If your HbA1c is above 8% and not improving, cell therapy is treating downstream damage while the upstream driver continues. Serious clinics will require documentation of reasonable glycemic control before treating diabetic neuropathy. Ones that don't are prioritizing their revenue over your outcome.
Regulatory status — Peripheral neuropathy
Neuropathy that hasn't responded to standard meds?
Send us your workup, HbA1c trend, and current therapies on WhatsApp. We'll help you evaluate options honestly.
Ask a question on WhatsApp